国金基金自2016年起开展量化实盘投资，并于2022年11月进入公募指增产品领域。据国金基金透露，其 量化策略以机器学习为核心，整合数百类因子，通过多维度信息挖掘、分层次策略适配和全流程监控， 持续优化模型并控制风险。2024年10月起，公司进一步收紧风格与行业暴露约束，在严控偏离的前提下 优化阿尔法模型。 在了解中证A500指数自身投资价值的基础上，市场也越来越关注如何借助相关产品来把握该指数的投 资机会。指数增强型产品作为一类兼顾指数Beta收益和量化选股Alpha收益的工具，已成为布局该指数 的重要方式。 国金基金表示，ETF力求紧密跟踪指数，追求最小偏离；而指增产品则在控制跟踪误差的基础上，借助 量化模型、行业轮动等方式力争实现超额收益。其收益来源可拆解为选股阿尔法（Alpha）和指数贝塔 （Beta），属于"被动打底、主动增强"型产品。这种策略的有效性在实际业绩中得到明显体现。数据显 示，截至9月17日，国金中证A500指数增强A今年以来收益率达27.50%，超额收益为7.74%。在57只同 类产品中高居第2，充分彰显了其量化模型的超额收益能力。 中证报中证网讯（记者 王宇露）今年以来A股持续回暖， ...

Core Viewpoint - Fengyuan Pharmaceutical (000153.SZ) released its semi-annual report for 2025, indicating a total institutional holding of 141 million shares, accounting for 30.39% of the company's total equity, with a slight decrease of 0.36 percentage points from the previous quarter [1] Institutional Holdings - As of August 21, 2025, seven institutional investors disclosed their holdings in Fengyuan Pharmaceutical, with a combined shareholding of 141 million shares [1] - The institutional investors include Anhui Wuwei Pharmaceutical Factory, Bengbu Tushan Enterprise Management Co., Ltd., Ma'anshan Fengyuan Enterprise Management Co., Ltd., Anhui Fengyuan Group Co., Ltd., Great Wall Guorong Investment Management Co., Ltd., BARCLAYS BANK PLC, and Guojin 300 Index Enhanced A [1] - The total institutional holding percentage decreased by 0.36 percentage points compared to the previous quarter [1] Public Fund and Foreign Investment - One new public fund disclosed its holdings this period, namely Guojin 300 Index Enhanced A [1] - Two public funds that were previously disclosed did not report this quarter, including Guojin CSI A500 Index Enhanced A and Dongxing Lianzhong One-Year Holding Period Mixed A [1] - One new foreign institution disclosed its holdings, BARCLAYS BANK PLC, while MORGAN STANLEY & CO. INTERNATIONAL PLC was not reported this quarter [1]